Nektar Therapeutics (NASDAQ:NKTR – Get Rating) had its price target trimmed by Canaccord Genuity Group from $25.00 to $6.00 in a report published on Wednesday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. NKTR has been the subject of several other research reports. Stifel Nicolaus cut Nektar Therapeutics from […]
Nektar Therapeutics (NASDAQ:NKTR – Get Rating) has earned an average recommendation of “Buy” from the nine brokerages that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued […]
/PRNewswire/ Nektar Therapeutics (NASDAQ: NKTR) today announced that its partner Eli Lilly & Company presented preliminary results from a Lilly-sponsored.
/PRNewswire/ Nektar Therapeutics (NASDAQ: NKTR) today announced that its partner Eli Lilly & Company presented preliminary results from a Lilly-sponsored.